ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.25
+0.34 (5.75%)
At close: Jan 30, 2026, 4:00 PM EST
6.27
+0.02 (0.32%)
After-hours: Jan 30, 2026, 7:59 PM EST
ImmunityBio Revenue
ImmunityBio had revenue of $32.06M in the quarter ending September 30, 2025, with 425.07% growth. This brings the company's revenue in the last twelve months to $82.56M, up 1,025.95% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$82.56M
Revenue Growth
+1,025.95%
P/S Ratio
64.78
Revenue / Employee
$122,667
Employees
673
Market Cap
6.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1,000.00 | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.78B |
| Caris Life Sciences | 649.06M |
| Mirum Pharmaceuticals | 471.79M |
| Rhythm Pharmaceuticals | 174.33M |
| Kymera Therapeutics | 43.74M |
| Crinetics Pharmaceuticals | 1.54M |
IBRX News
- 9 days ago - ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy - Business Wire
- 12 days ago - FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer - Benzinga
- 12 days ago - Top 3 Health Care Stocks You May Want To Dump In January - Benzinga
- 12 days ago - ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Business Wire
- 16 days ago - ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline - Benzinga
- 16 days ago - ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So - Benzinga
- 16 days ago - Looking For A Short Squeeze? 10 Stocks Ready To Rocket - Benzinga